Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 6
2005 5
2006 7
2007 5
2008 9
2009 4
2010 10
2011 6
2012 6
2013 4
2014 6
2015 4
2016 4
2017 6
2018 8
2019 4
2020 9
2021 6
2022 5
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Results by year

Filters applied: . Clear all
Page 1
Characterization of Non-amyloidogenic G101S Transthyretin.
Wakita Y, Sato T, Chosa K, Suico MA, Sasaki R, Kawano S, Hashimoto N, Teranishi Y, Imai Y, Morioka H, Shuto T, Kai H. Wakita Y, et al. Among authors: suico ma. Biol Pharm Bull. 2018;41(4):628-636. doi: 10.1248/bpb.b17-01021. Biol Pharm Bull. 2018. PMID: 29607936 Free article.
Metformin ameliorates the severity of experimental Alport syndrome.
Omachi K, Kaseda S, Yokota T, Kamura M, Teramoto K, Kuwazuru J, Kojima H, Nohara H, Koyama K, Ohtsuki S, Misumi S, Takeo T, Nakagata N, Li JD, Shuto T, Suico MA, Miner JH, Kai H. Omachi K, et al. Among authors: suico ma. Sci Rep. 2021 Mar 29;11(1):7053. doi: 10.1038/s41598-021-86109-1. Sci Rep. 2021. PMID: 33782421 Free PMC article.
Novel Keap1-Nrf2 Protein-Protein Interaction Inhibitor UBE-1099 Ameliorates Progressive Phenotype in Alport Syndrome Mouse Model.
Kaseda S, Sannomiya Y, Horizono J, Kuwazuru J, Suico MA, Ogi S, Sasaki R, Sunamoto H, Fukiya H, Nishiyama H, Kamura M, Niinou S, Koyama Y, Nara F, Shuto T, Onuma K, Kai H. Kaseda S, et al. Among authors: suico ma. Kidney360. 2021 Dec 1;3(4):687-699. doi: 10.34067/KID.0004572021. eCollection 2022 Apr 28. Kidney360. 2021. PMID: 35721612 Free PMC article.
Combinatorial screening for therapeutics in ATTRv amyloidosis identifies naphthoquinone analogues as TTR-selective amyloid disruptors.
Sasaki R, Suico MA, Chosa K, Teranishi Y, Sato T, Kagami A, Kotani S, Kato H, Hitora Y, Tsukamoto S, Yamashita T, Yokoyama T, Mizuguchi M, Kai H, Shuto T. Sasaki R, et al. Among authors: suico ma. J Pharmacol Sci. 2023 Jan;151(1):54-62. doi: 10.1016/j.jphs.2022.11.004. Epub 2022 Nov 29. J Pharmacol Sci. 2023. PMID: 36522123 Free article.
Metformin suppresses epithelial sodium channel hyperactivation and its associated phenotypes in a mouse model of obstructive lung diseases.
Nakashima R, Nohara H, Takahashi N, Nasu A, Hayashi M, Kishimoto T, Kamei S, Fujikawa H, Maruta K, Kawakami T, Eto Y, Ueno-Shuto K, Suico MA, Kai H, Shuto T. Nakashima R, et al. Among authors: suico ma. J Pharmacol Sci. 2022 Jun;149(2):37-45. doi: 10.1016/j.jphs.2022.03.002. Epub 2022 Mar 23. J Pharmacol Sci. 2022. PMID: 35512853 Free article.
Podocyte p53 Limits the Severity of Experimental Alport Syndrome.
Fukuda R, Suico MA, Kai Y, Omachi K, Motomura K, Koga T, Komohara Y, Koyama K, Yokota T, Taura M, Shuto T, Kai H. Fukuda R, et al. Among authors: suico ma. J Am Soc Nephrol. 2016 Jan;27(1):144-57. doi: 10.1681/ASN.2014111109. Epub 2015 May 12. J Am Soc Nephrol. 2016. PMID: 25967122 Free PMC article.
CyclosporinA Derivative as Therapeutic Candidate for Alport Syndrome by Inducing Mutant Type IV Collagen Secretion.
Kuwazuru J, Suico MA, Omachi K, Kojima H, Kamura M, Kaseda S, Kawahara T, Hitora Y, Kato H, Tsukamoto S, Wada M, Asano T, Kotani S, Nakajima M, Misumi S, Sannomiya Y, Horizono J, Koyama Y, Owaki A, Shuto T, Kai H. Kuwazuru J, et al. Among authors: suico ma. Kidney360. 2023 Jul 1;4(7):909-917. doi: 10.34067/KID.0000000000000134. Epub 2023 May 5. Kidney360. 2023. PMID: 37143203 Free PMC article.
104 results